Navigation Links
Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept)
Date:11/12/2007

- Data presented at American College of Rheumatology Annual Congress -

BOSTON, Nov. 12 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE: BMY) today announced the results of three post-hoc analyses from two Phase III pivotal trials that showed ORENCIA(R) (abatacept) improved daily activity participation, such as work or household chores, physical and social-role independence and sleep quality in adult rheumatoid arthritis (RA) patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs), such as methotrexate (MTX) or tumor necrosis factor (TNF) antagonists.

These data are from post-hoc analyses of two Phase III pivotal trials investigating ORENCIA: AIM (Abatacept in Inadequate responders to Methotrexate) and ATTAIN (Abatacept Trial in Treatment of Anti-TNF Inadequate Responders).

"The chronic nature of RA can have a significant impact on a person's health-related quality of life, including independence, ability to perform daily activities and sleep quality," said George Wells, M.Sc., Ph.D., Professor of the Department of Epidemiology and Community Medicine, University of Ottawa.

About the Data

Poster presentations of these analyses of the AIM (n=433 for ORENCIA plus MTX; n=219 for placebo plus MTX) and ATTAIN (n=258 for ORENCIA plus DMARDs; n=133 for placebo plus DMARDs) studies evaluating health-related quality of life improvement in daily activity participation, independence and sleep quality in RA patients treated with ORENCIA(R) (abatacept) were presented last week at the ACR Annual Scientific Meeting in Boston, MA.

An analysis of the AIM and ATTAIN studies presented by Li, et al, looked at RA patients' ability to particip
'/>"/>

SOURCE Bristol-Myers Squibb Company
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
2. New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients with Epilepsy
3. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
4. Potent Hepatitis C Virus Inhibitors Show Efficacy and Potential for Once Daily Dosing in Preclinical Studies
5. ISTA Pharmaceuticals Presents Results from Two Phase III Clinical Trials of Xibrom(TM) QD (Once-daily) Formulation at the American Academy of Ophthalmology Annual Meeting
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
8. Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria
9. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
10. Oritavancin Demonstrates Potent and Rapid In Vitro Activity Against MRSA, VRE and Other Strains of Resistant Bacteria
11. Proteolix Initiates Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2009)...URG, South Africa, Nov. 26 The 200... Year Award in the Generic Pharmaceutical Market i...,, (Logo: http://www.newscom.com/cgi-bin/prnh/...r Award, the following criteria were used to bench...itors: growth strategy and implementation, degree ...
(Date:11/25/2009)...Colo., Nov. 25 Heska Cor... advanced diagnostic and specialty products to t... with Roche Diagnostics Corporation for the supply...for the veterinary market. ,, (Logo: http:...) ,, "Heska and Roche share the same passion fo...
(Date:11/25/2009)...PHIA, Nov. 25 ERT (Nasda...Kelvey, the Company,s President and CEO, and Keith...nd CFO, are scheduled to present at the 21st Annua...EST on December 1, 2009 in New York City, New York...tion by visiting the Company,s corporate website a...
Breaking Medicine Technology:Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 2Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 3Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 4Heska Announces Supply Agreement With Roche Diagnostics 2Heska Announces Supply Agreement With Roche Diagnostics 3ERT to Present at the 21st Annual Piper Jaffray Health Care Conference on December 1, 2009 2UC San Diego researchers reverse pulmonary arterial hypertension in mouse models 60038 1UC San Diego researchers reverse pulmonary arterial hypertension in mouse models 60038 2Master regulator found for regenerating nerve fibers in live animals 10511 1Master regulator found for regenerating nerve fibers in live animals 10511 2Is Smoking Tougher on Women 3F 60033 1Is Smoking Tougher on Women 3F 60033 2Is Smoking Tougher on Women 3F 60033 3
(Date:11/28/2009)...hange after 30-minute psychosocial intervention, s...y News) -- A program that gets persistent drunk dr...rous behavior may lead to significant and long-las... study included 184 men and women with two or more...omly assigned to one of two interventions. The fir...
(Date:11/27/2009)...s Ltd. today issued its latest biochemical analysi...he lethality of the virus has dropped from its pea...break in the spring of 2009 to resting non-epidemi...ectivity count, however, remains increased. , ...009 -- Biotech firm Replikins Ltd., which has anal...
(Date:11/27/2009)...ewswire-FirstCall/ -- Shamir Optical Industry Ltd.... of innovative products and technology to the opht... of directors had declared a dividend distribution...mately NIS 37.62 million based on the November 25,...mately US$ 0.609 (approximately NIS 2.3 based on t...
(Date:11/27/2009)...announced today that Spectrum Health (Grand Rapids...orthopedic templating solution and its TraumaCad E... (PRWEB) November 27, 2009 -- Voyant Health&trade...ds, Michigan) has licensed its TraumaCad Enterpris... Extend workflow solution, to allow its orthopedic...
(Date:11/26/2009)...ire/ -- The diabetes population in the United Stat...nnual medical spending on the disease is projected...according to a study published in the December iss...betes ® Program (NCDP), a program of Novo Nor... University of Chicago. ,, According to the for...
Breaking Medicine News(10 mins):Health News:Drunk Drivers May Respond to Brief Motivational Interview 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 3Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 4Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 5Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 2Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 3Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 2Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 3Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 4
...ore than a dozen,indications of interest in the Re...and Portneuf Medical Center (PMC), the County Comm...s medical staff, has named two,finalists as possib...osed shared ownership and governance structure wit...
...g statement was issued,today by the law firm of Sc... hereby given that a class action lawsuit was file...le District of Tennessee on behalf,of all purchase...lass Period")., If you wish to discuss this actio...
...Chicago is one of 11 centers in the United States,...linical Islet Transplant Consortium funded by the ...rchers have begun clinical studies to test new app...tients with type 1 diabetes depend on multiple dai...
...lation that would cut $6.6 million,from Medicare A...ly 8 Seniors across New,Hampshire are speaking ou...program in legislation being considered in the U.S...are choices., New Hampshire seniors enrolled in M...
...urgh-led researchers could provide new insight int...rtic arch deformity and arteriovenous malformation... 15 edition of Developmental Biology . , Led by ...tion of how aortic arch vessels form and, in a sep...
...,watchful waiting, study shows , , TUESDAY...n therapy used for localized prostate cancer may n...ond those seen with a simple "wait-and-see" approa...r-specific survival rate. , "This might give pause...
Other Medicine News:Health News:PMC and County Announce Potential Capital Partners for Hospital 2Health News:PMC and County Announce Potential Capital Partners for Hospital 3Health News:PMC and County Announce Potential Capital Partners for Hospital 4Health News:PMC and County Announce Potential Capital Partners for Hospital 5Health News:Shareholder Class Action Filed Against Healthways Inc. By The Law Firm of Schiffrin Barroway Topaz & Kessler, LLP 2Health News:Shareholder Class Action Filed Against Healthways Inc. By The Law Firm of Schiffrin Barroway Topaz & Kessler, LLP 3Health News:UIC in NIH-funded islet transplantation study for type 1 diabetes 2Health News:New Hampshire Seniors Speak Out Against Medicare Advantage Cuts 2Health News:Pitt-led research provides insight into development of congenital circulatory defects 2Health News:Hormone Therapy Shows Little Benefit Against Prostate Cancer 2Health News:Hormone Therapy Shows Little Benefit Against Prostate Cancer 3
Terry-Schanzlin Astigmatome - Speculum Sets
...l Temporary Pacing Lead is designed to provide the...sing and pacing capabilities of the Medtronic Mode...treamline Temporary Pacing Leads are designed to p...ing and after cardiac surgery. Different models we...
...y of temporary sensing and pacing leads. Our engin...ing leads and improved upon the features that make...ue. , ,The Model 6491 Unipolar Pediatric Tempo...and ventricular sensing and pacing during and afte...
Carpentier-Edwards Classic Mitral Annuloplasty Rings
Medicine Products: